Literature DB >> 9634823

Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types.

T J Wickham1, P W Roelvink, D E Brough, I Kovesdi.   

Abstract

Adenovirus (Ad) is used as a vector for gene delivery in therapies involving genetic disease, vascular disease, and cancer. The first step for efficient gene transfer is effective virus binding to the target cells. We have found that Ad-mediated gene delivery to multiple cell types is much less efficient compared to epithelial-derived cells. Low gene delivery to nonepithelial cell types was directly correlated to a deficiency of the cellular receptor which mediates Ad binding. To overcome this inefficiency we constructed a new virus, AdPK, that contains a heparin-binding domain that targets the virus to broadly expressed, heparan-containing cellular receptors. AdPK delivers genes to multiple cell types at markedly higher efficiencies than unmodified Ad. Viruses with enhanced attachment characteristics significantly improve gene transfer efficiency and may expand the tissues amenable to efficient Ad-mediated gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9634823     DOI: 10.1038/nbt1196-1570

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  82 in total

1.  Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors.

Authors:  N Miyazawa; P L Leopold; N R Hackett; B Ferris; S Worgall; E Falck-Pedersen; R G Crystal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.

Authors:  D A Einfeld; D E Brough; P W Roelvink; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

3.  Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer.

Authors:  R J Pickles; J A Fahrner; J M Petrella; R C Boucher; J M Bergelson
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 5.  Gene transfer for cystic fibrosis.

Authors:  M J Welsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

6.  CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts.

Authors:  C Hidaka; E Milano; P L Leopold; J M Bergelson; N R Hackett; R W Finberg; T J Wickham; I Kovesdi; P Roelvink; R G Crystal
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

7.  Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenovirus receptor-positive cell lines.

Authors:  Toshiro Seki; Igor Dmitriev; Elena Kashentseva; Koichi Takayama; Marianne Rots; Kaori Suzuki; David T Curiel
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types.

Authors:  Clare E Thomas; Penny Edwards; Thomas J Wickham; Maria G Castro; Pedro R Lowenstein
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

10.  Metabolic biotinylation of recombinant proteins in mammalian cells and in mice.

Authors:  M B Parrott; M A Barry
Journal:  Mol Ther       Date:  2000-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.